1. Centers for Disease Control and Prevention. HIV surveillance report, 2017. 2018; 29; Retrieved From:
http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
. Accessed 15 Jan 2019.
2. Florida Department of Health. Epidemiologic profile report. 2018; Retrieved From:
http://www.floridahealth.gov/diseases-and-conditions/aids/surveillance/epi-profiles/index.html
. Accessed 30 Apr 2019.
3. Food and Drug Administration (FDA). FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012; Retrieved From:
https://wayback.archive-it.org/7993/20170112032741/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm
. Accessed 15 Sept 2018.
4. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
5. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.